1 Letterman Dr
9 articles with Sonoma BioTherapeutics
Sonoma Biotherapeutics, an immune tolerance company focused on the development of novel regulatory T cell therapies for autoimmune and inflammatory disease, announced the appointment of Heidi Hagen, MBA as Chief Technical Officer.
Sonoma Biotherapeutics Expands Leadership Team with the Appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary
Sonoma Biotherapeutics today announced the appointment of Doug Sheehy, J.D., as Chief Legal Officer and Secretary.
8/11/2021Check out where the money went in the life sciences industry this week.
Sonoma Biotherapeutics Raises $265 Million in an Oversubscribed Series B Financing to Translate the Promise of Cell Therapy into Curative Medicines for Autoimmune and Other Inflammatory Diseases
Sonoma Biotherapeutics’ platform and product candidates aim to restore immune system balance through complementary regulatory T cell (T reg ) therapy and effector T cell (T eff ) conditioning
Sonoma BioTherapeutics continues to work toward its goal of restoring immune system balance through complementary regulatory T cell therapy and effector T cell conditioning, this time with the help of an oversubscribed Series B round.
BioSpace is proud to present its NextGen Bio “Class of 2021,” a list of up-and-coming life sciences companies in North America that recently launched.
Sonoma Biotherapeutics Expands Series A Financing to $70 Million and Appoints Key Executives to Advance Regulatory T-cell Therapies in Autoimmune and Degenerative Diseases
Sonoma Biotherapeutics, a privately held company developing regulatory T-cell therapies for autoimmune and degenerative diseases, announced that it has raised an additional $30 million from investors in its Series A financing, bringing the total to $70 million.
Sonoma Biotherapeutics launches with $40 million in Series A funding to advance regulatory T cell therapy in autoimmune and degenerative diseases
Company founded by four pioneers of Treg cell biology and cell therapy and financed by a syndicate of leading biotech investors
2/6/2020Jeffrey Bluestone, the noted scientific researcher and pioneer in understanding T-cell activation and immune tolerance in cancer patients, has stepped down from his role as chief executive of the Parker Institute for Cancer Immunotherapy to launch Sonoma Biotherapeutics.